Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study

Fig. 2

Effect of prucalopride on defecation. Number of complete spontaneous bowel movements recorded by patients during the 1-month consumption of prucalopride 2 mg/day or the 1-month period without treatment. The plot represents the values adjusted for the mean of used laxatives. Dashed lines indicate the occurrence of ≥3 evacuations/week (12/month)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us